NON-SMALL CELL LUNG CANCER (NSCLC)

This early-stage study tested a new drug called AZD0022, alone or with other cancer drugs, in people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic mutation called KRASG12D. The main goals were to check the drug's safety and …

This study tested a combination of two immunotherapy drugs (tiragolumab and atezolizumab) given before and after surgery for people with early-stage non-small cell lung cancer. The goal was to see if the treatment was safe and helped shrink tumors before surgery. The study was te…

This study tested adding tiragolumab to atezolizumab in people with non-small cell lung cancer who had surgery and chemotherapy. The goal was to see if the combination worked better than atezolizumab alone. The trial was stopped early, and only 56 people took part. The main focus…

This study tested a new drug called TAK-186 in 95 adults with advanced or metastatic cancers of the head and neck, lung, or colon that could not be removed by surgery. The main goal was to check for side effects and find the best dose. The study was stopped early, so results are …

This study tested an experimental drug called cofetuzumab pelidotin for people with a specific type of advanced lung cancer (non-small cell lung cancer) that had returned after other treatments. The drug was designed to target a protein called PTK7 found on cancer cells. The stud…

This study tested a wearable device that delivers low-intensity electric fields (TTFields) combined with the immunotherapy drug pembrolizumab in people with advanced non-small cell lung cancer that had already been treated with chemotherapy and a PD-1/PD-L1 inhibitor. The goal wa…